<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02465489</url>
  </required_header>
  <id_info>
    <org_study_id>LA51-0115</org_study_id>
    <nct_id>NCT02465489</nct_id>
  </id_info>
  <brief_title>Comparison of Deferiprone Extended Release Tablets and Ferriprox Immediate Release Tablets in Healthy Volunteers</brief_title>
  <official_title>Single-dose Pharmacokinetic Study of Deferiprone Extended Release Tablets Versus Ferriprox Immediate Release Tablets Under Fasting and Fed Conditions in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ApoPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ApoPharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to look at the pharmacokinetics of a new formulation of
      deferiprone (deferiprone extended release tablets) under fed and fasting conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, open-label, randomized, 5-period, 5-sequence study of the
      pharmacokinetics of a new formulation of deferiprone, extended release tablets, in twenty
      healthy volunteers. In each study period, blood samples for pharmacokinetics assessment will
      be collected pre-dose and over 24 hours post-dose. Safety will be assessed throughout the
      study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax for Serum Deferiprone</measure>
    <time_frame>Samples were collected pre-dose and at 0.25, 0.5, 0.75, 1.0, 1.33, 1.66, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 8.0, 12.0, 16.0, and 24.0 hours post-dose.</time_frame>
    <description>Maximum measured serum concentration. Blood samples will be collected pre-dose and over a 24-hour interval post-dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax for Serum Deferiprone</measure>
    <time_frame>Samples were collected pre-dose and at 0.25, 0.5, 0.75, 1.0, 1.33, 1.66, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 8.0, 12.0, 16.0, and 24.0 hours post-dose.</time_frame>
    <description>Time of maximum observed serum concentration. Blood samples will be collected pre-dose and over a 24-hour interval post-dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞for Serum Deferiprone</measure>
    <time_frame>Samples were collected pre-dose and at 0.25, 0.5, 0.75, 1.0, 1.33, 1.66, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 8.0, 12.0, 16.0, and 24.0 hours post-dose.</time_frame>
    <description>Area under the serum concentration time curve extrapolated to infinity. Blood samples will be collected pre-dose and over a 24-hour interval post-dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Adverse Events (AEs)</measure>
    <time_frame>Throughout the trial, from the time of the first dose until the last study visit (Day 36 or early termination)</time_frame>
    <description>Number of subjects with AEs. AEs will include clinically significant changes from baseline in vital signs, 12-lead ECG, physical examinations, and laboratory tests.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>ER, fasting conditions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single 1000 mg dose of deferiprone extended release tablet formulation administered under fasting conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ER, fed conditions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single 1000 mg dose of deferiprone extended release tablet formulation administered under fed conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ER half-tablets, fed conditions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single 1000 mg dose of deferiprone extended release tablet formulation (one 1000 mg tablet divided in two) administered under fed conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IR, fasting conditions</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single 1000 mg dose of deferiprone immediate release tablet formulation administered under fasting conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IR, fed conditions</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single 1000 mg dose of deferiprone immediate release tablet formulation administered under fed conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferiprone extended release</intervention_name>
    <description>Deferiprone 1000 mg extended release tablet formulation</description>
    <arm_group_label>ER, fasting conditions</arm_group_label>
    <arm_group_label>ER, fed conditions</arm_group_label>
    <arm_group_label>ER half-tablets, fed conditions</arm_group_label>
    <other_name>Deferiprone extended release tablet formulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferiprone immediate release</intervention_name>
    <description>Ferriprox (deferiprone) 500 mg immediate release tablet formulation</description>
    <arm_group_label>IR, fasting conditions</arm_group_label>
    <arm_group_label>IR, fed conditions</arm_group_label>
    <other_name>Ferriprox immediate release tablet formulation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female aged ≥18 to &lt;50 years

          2. A female volunteer of childbearing potential must agree to use an accepted
             contraceptive regimen from at least 28 days prior to the first administration of the
             study drug until at least 30 days after the last dose of the study drug

          3. A sexually active male must agree that he and/or his female partner will use a
             medically acceptable method of contraception throughout the study and for at least 30
             days following drug administration

          4. Body mass index (BMI) greater than or equal to 18.5 kg/m^2 and below 30.0 kg/m^2

          5. Body weight of at least 60 kg

          6. Non- or ex smoker

          7. Clinical laboratory values within the laboratory's stated normal range; if not within
             this range, an abnormal value must be without any clinical significance

          8. Have no clinically significant diseases captured in the medical history, or evidence
             of clinically significant findings on physical examination and/or clinical laboratory
             evaluations (hematology, general biochemistry, coagulation, ECG, and urinalysis)

        Exclusion Criteria:

          1. Pregnant or breastfeeding

          2. Absolute neutrophil count (ANC) &lt; 1.8 x 109/L at screening (no repeat can be
             performed)

          3. History of significant hypersensitivity to deferiprone or any related products
             (including excipients of the formulations) as well as severe hypersensitivity
             reactions (such as angioedema) to any drugs

          4. History or presence of gastrointestinal, liver or kidney disease, or any other
             conditions known to interfere with the absorption, distribution, metabolism, or
             excretion of drugs or known to potentiate or predispose to undesired effects

          5. Presence of significant cardiovascular, pulmonary, hematologic, neurological,
             psychiatric, endocrine, immunologic or dermatologic disease

          6. Suicidal tendency, history of seizures, history of head trauma with coma or
             craniotomy/trepanation, state of confusion, or clinically relevant psychiatric
             diseases

          7. Presence of out-of-range cardiac interval (PR &lt; 110 msec, PR &gt; 220 msec, QRS &lt; 60
             msec, QRS &gt;119 msec and QTcF &gt; 450 msec for males and &gt; 460 msec for females) on the
             screening ECG or other clinically significant ECG abnormalities

          8. Maintenance therapy with any drug or significant history of drug dependency or alcohol
             abuse (&gt; 3 units of alcohol per day, intake of excessive alcohol, acute or chronic)

          9. Any clinically significant illness in the previous 28 days before Day 1 of this study

         10. Use of any enzyme-modifying drugs, including strong inhibitors of cytochrome P450
             (CYP) enzymes (such as cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin,
             fluconazole, ketoconazole, diltiazem and HIV antivirals) and strong inducers of CYP
             enzymes (such as barbiturates, carbamazepine, glucocorticoids, phenytoin, rifampin and
             St John's Wort), in the previous 28 days before Day 1 of this study

         11. Any history of tuberculosis and/or prophylaxis for tuberculosis

         12. Serum ferritin value below the normal limit of the reference laboratory at screening

         13. Positive urine screening of alcohol and/or drugs of abuse

         14. Positive results on HIV Ag/Ab Combo, Hepatitis B surface Antigen (HBsAG (B) (hepatitis
             B)) or anti-Hepatitis C Virus (HCV (C)) tests

         15. Positive result on a serum pregnancy test

         16. Receipt of an investigational product in another clinical trial in the previous 28
             days before Day 1 of this study

         17. Donation of 50 mL or more of blood in the previous 28 days before Day 1 of this study
             or donation of 500 mL or more of blood (Canadian Blood Services, Hema-Quebec, clinical
             studies, etc.) in the previous 56 days before Day 1 of this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Sicard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Algorithme Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Algorithme Pharma Inc.</name>
      <address>
        <city>Mount-Royal</city>
        <state>Quebec</state>
        <zip>H3P 3P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2015</study_first_submitted>
  <study_first_submitted_qc>June 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2015</study_first_posted>
  <results_first_submitted>December 18, 2015</results_first_submitted>
  <results_first_submitted_qc>December 18, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 26, 2016</results_first_posted>
  <last_update_submitted>January 27, 2016</last_update_submitted>
  <last_update_submitted_qc>January 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>deferiprone</keyword>
  <keyword>deferiprone extended release formulation</keyword>
  <keyword>pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deferiprone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Healthy Volunteers</title>
          <description>Subjects were randomized to receive the following five treatments in different orders, with a 7-day washout period between treatments::
A: Deferiprone ER tablets under fasting conditions B: Deferiprone ER tablets under fed conditions C: Deferiprone ER tablets administered as half-tablets under fed conditions D: Ferriprox IR tablets under fasting conditions E: Ferriprox IR tablets under fed conditions
The sequences were as follows;
Sequence 1 (n=4): A-B-E-C-D
Sequence 2 (n=4): B-C-A-D-E
Sequence 3 (n=4): C-D-B-E-A
Sequence 4 (n=4): D-E-C-A-B
Sequence 5 (n=4): E-A-D-B-C</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Healthy Volunteers</title>
          <description>Subjects were randomized to receive five treatments in different orders:
deferiprone ER tablets under fasting conditions
deferiprone ER tablets under fed conditions
deferiprone ER tablets administered as half-tablets under fed conditions
Ferriprox IR tablets under fasting conditions
Ferriprox IR tablets under fed conditions</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax for Serum Deferiprone</title>
        <description>Maximum measured serum concentration. Blood samples will be collected pre-dose and over a 24-hour interval post-dose</description>
        <time_frame>Samples were collected pre-dose and at 0.25, 0.5, 0.75, 1.0, 1.33, 1.66, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 8.0, 12.0, 16.0, and 24.0 hours post-dose.</time_frame>
        <population>The pharmacokinetic population included subjects who provided evaluable data for at least two study periods.</population>
        <group_list>
          <group group_id="O1">
            <title>Extended Release, Fasting Conditions</title>
            <description>A single 1000 mg dose of deferiprone extended release tablet formulation administered following a 10-hour fast
Deferiprone extended release: Deferiprone 1000 mg extended release tablet formulation</description>
          </group>
          <group group_id="O2">
            <title>Extended Release, Fed Conditions</title>
            <description>A single 1000 mg dose of deferiprone extended release tablet formulation administered following a high-fat breakfast
Deferiprone extended release: Deferiprone 1000 mg extended release tablet formulation</description>
          </group>
          <group group_id="O3">
            <title>Extended Release Half-tablets, Fed Conditions</title>
            <description>A single 1000 mg dose of deferiprone extended release tablet formulation (one 1000 mg tablet divided in two) administered following a high-fat breakfast
Deferiprone extended release: Deferiprone 1000 mg extended release tablet formulation</description>
          </group>
          <group group_id="O4">
            <title>Immediate Release, Fasting Conditions</title>
            <description>A single 1000 mg dose of Ferriprox immediate release tablet formulation administered following a 10-hour fast
Deferiprone immediate release: Ferriprox (deferiprone) 500 mg immediate release tablet formulation</description>
          </group>
          <group group_id="O5">
            <title>Immediate Release, Fed Conditions</title>
            <description>A single 1000 mg dose of Ferriprox immediate release tablet formulation administered following a high-fat breakfast
Deferiprone immediate release: Ferriprox (deferiprone) 500 mg immediate release tablet formulation</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax for Serum Deferiprone</title>
          <description>Maximum measured serum concentration. Blood samples will be collected pre-dose and over a 24-hour interval post-dose</description>
          <population>The pharmacokinetic population included subjects who provided evaluable data for at least two study periods.</population>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.89" spread="1.47"/>
                    <measurement group_id="O2" value="2.76" spread="1.45"/>
                    <measurement group_id="O3" value="3.02" spread="1.03"/>
                    <measurement group_id="O4" value="13.89" spread="3.84"/>
                    <measurement group_id="O5" value="9.77" spread="3.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax for Serum Deferiprone</title>
        <description>Time of maximum observed serum concentration. Blood samples will be collected pre-dose and over a 24-hour interval post-dose</description>
        <time_frame>Samples were collected pre-dose and at 0.25, 0.5, 0.75, 1.0, 1.33, 1.66, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 8.0, 12.0, 16.0, and 24.0 hours post-dose.</time_frame>
        <population>The pharmacokinetic population included subjects who provided evaluable data for at least two study periods</population>
        <group_list>
          <group group_id="O1">
            <title>Extended Release, Fasting Conditions</title>
            <description>A single 1000 mg dose of deferiprone extended release tablet formulation administered following a 10-hour fast
Deferiprone extended release: Deferiprone 1000 mg extended release tablet formulation</description>
          </group>
          <group group_id="O2">
            <title>Extended Release, Fed Conditions</title>
            <description>A single 1000 mg dose of deferiprone extended release tablet formulation administered following a high-fat breakfast
Deferiprone extended release: Deferiprone 1000 mg extended release tablet formulation</description>
          </group>
          <group group_id="O3">
            <title>Extended Release Half-tablets, Fed Conditions</title>
            <description>A single 1000 mg dose of deferiprone extended release tablet formulation (one 1000 mg tablet divided in two) administered following a high-fat breakfast
Deferiprone extended release: Deferiprone 1000 mg extended release tablet formulation</description>
          </group>
          <group group_id="O4">
            <title>Immediate Release, Fasting Conditions</title>
            <description>A single 1000 mg dose of Ferriprox immediate release tablet formulation administered following a 10-hour fast
Deferiprone immediate release: Ferriprox (deferiprone) 500 mg immediate release tablet formulation</description>
          </group>
          <group group_id="O5">
            <title>Immediate Release, Fed Conditions</title>
            <description>A single 1000 mg dose of Ferriprox immediate release tablet formulation administered following a high-fat breakfast
Deferiprone immediate release: Ferriprox (deferiprone) 500 mg immediate release tablet formulation</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax for Serum Deferiprone</title>
          <description>Time of maximum observed serum concentration. Blood samples will be collected pre-dose and over a 24-hour interval post-dose</description>
          <population>The pharmacokinetic population included subjects who provided evaluable data for at least two study periods</population>
          <units>Hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.63" spread="1.10"/>
                    <measurement group_id="O2" value="15.66" spread="9.33"/>
                    <measurement group_id="O3" value="8.29" spread="7.25"/>
                    <measurement group_id="O4" value="0.94" spread="0.63"/>
                    <measurement group_id="O5" value="1.91" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-∞for Serum Deferiprone</title>
        <description>Area under the serum concentration time curve extrapolated to infinity. Blood samples will be collected pre-dose and over a 24-hour interval post-dose.</description>
        <time_frame>Samples were collected pre-dose and at 0.25, 0.5, 0.75, 1.0, 1.33, 1.66, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 8.0, 12.0, 16.0, and 24.0 hours post-dose.</time_frame>
        <population>The pharmacokinetic population included subjects who provided evaluable data for at least two study periods</population>
        <group_list>
          <group group_id="O1">
            <title>Extended Release, Fasting Conditions</title>
            <description>A single 1000 mg dose of deferiprone extended release tablet formulation administered following a 10-hour fast
Deferiprone extended release: Deferiprone 1000 mg extended release tablet formulation</description>
          </group>
          <group group_id="O2">
            <title>Extended Release, Fed Conditions</title>
            <description>A single 1000 mg dose of deferiprone extended release tablet formulation administered following a high-fat breakfast
Deferiprone extended release: Deferiprone 1000 mg extended release tablet formulation</description>
          </group>
          <group group_id="O3">
            <title>Extended Release Half-tablets, Fed Conditions</title>
            <description>A single 1000 mg dose of deferiprone extended release tablet formulation (one 1000 mg tablet divided in two) administered following a high-fat breakfast
Deferiprone extended release: Deferiprone 1000 mg extended release tablet formulation</description>
          </group>
          <group group_id="O4">
            <title>Immediate Release, Fasting Conditions</title>
            <description>A single 1000 mg dose of Ferriprox immediate release tablet formulation administered following a 10-hour fast
Deferiprone immediate release: Ferriprox (deferiprone) 500 mg immediate release tablet formulation</description>
          </group>
          <group group_id="O5">
            <title>Immediate Release, Fed Conditions</title>
            <description>A single 1000 mg dose of Ferriprox immediate release tablet formulation administered following a high-fat breakfast
Deferiprone immediate release: Ferriprox (deferiprone) 500 mg immediate release tablet formulation</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-∞for Serum Deferiprone</title>
          <description>Area under the serum concentration time curve extrapolated to infinity. Blood samples will be collected pre-dose and over a 24-hour interval post-dose.</description>
          <population>The pharmacokinetic population included subjects who provided evaluable data for at least two study periods</population>
          <units>ug*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.42" spread="6.68"/>
                    <measurement group_id="O2" value="40.52" spread="0.77"/>
                    <measurement group_id="O3" value="31.72" spread="8.21"/>
                    <measurement group_id="O4" value="34.81" spread="6.81"/>
                    <measurement group_id="O5" value="33.02" spread="7.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Adverse Events (AEs)</title>
        <description>Number of subjects with AEs. AEs will include clinically significant changes from baseline in vital signs, 12-lead ECG, physical examinations, and laboratory tests.</description>
        <time_frame>Throughout the trial, from the time of the first dose until the last study visit (Day 36 or early termination)</time_frame>
        <population>The safety population included all subjects who received at least one of the investigational products under study</population>
        <group_list>
          <group group_id="O1">
            <title>Extended Release, Fasting Conditions</title>
            <description>A single 1000 mg dose of deferiprone extended release tablet formulation administered following a 10-hour fast
Deferiprone extended release: Deferiprone 1000 mg extended release tablet formulation</description>
          </group>
          <group group_id="O2">
            <title>Extended Release, Fed Conditions</title>
            <description>A single 1000 mg dose of deferiprone extended release tablet formulation administered following a high-fat breakfast
Deferiprone extended release: Deferiprone 1000 mg extended release tablet formulation</description>
          </group>
          <group group_id="O3">
            <title>Extended Release Half-tablets, Fed Conditions</title>
            <description>A single 1000 mg dose of deferiprone extended release tablet formulation (one 1000 mg tablet divided in two) administered following a high-fat breakfast
Deferiprone extended release: Deferiprone 1000 mg extended release tablet formulation</description>
          </group>
          <group group_id="O4">
            <title>Immediate Release, Fasting Conditions</title>
            <description>A single 1000 mg dose of Ferriprox immediate release tablet formulation administered following a 10-hour fast
Deferiprone immediate release: Ferriprox (deferiprone) 500 mg immediate release tablet formulation</description>
          </group>
          <group group_id="O5">
            <title>Immediate Release, Fed Conditions</title>
            <description>A single 1000 mg dose of Ferriprox immediate release tablet formulation administered following a high-fat breakfast
Deferiprone immediate release: Ferriprox (deferiprone) 500 mg immediate release tablet formulation</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Adverse Events (AEs)</title>
          <description>Number of subjects with AEs. AEs will include clinically significant changes from baseline in vital signs, 12-lead ECG, physical examinations, and laboratory tests.</description>
          <population>The safety population included all subjects who received at least one of the investigational products under study</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the administration of the first dose in period 1 until the end-of-study visit</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Extended Release, Fasting Conditions</title>
          <description>A single 1000 mg dose of deferiprone extended release tablet formulation administered following a 10-hour fast
Deferiprone extended release: Deferiprone 1000 mg extended release tablet formulation</description>
        </group>
        <group group_id="E2">
          <title>Extended Release, Fed Conditions</title>
          <description>A single 1000 mg dose of deferiprone extended release tablet formulation administered following a high-fat breakfast
Deferiprone extended release: Deferiprone 1000 mg extended release tablet formulation</description>
        </group>
        <group group_id="E3">
          <title>Extended Release Half-tablets, Fed Conditions</title>
          <description>A single 1000 mg dose of deferiprone extended release tablet formulation (one 1000 mg tablet divided in two) administered following a high-fat breakfast
Deferiprone extended release: Deferiprone 1000 mg extended release tablet formulation</description>
        </group>
        <group group_id="E4">
          <title>Immediate Release, Fasting Conditions</title>
          <description>A single 1000 mg dose of Ferriprox immediate release tablet formulation administered following a 10-hour fast
Deferiprone immediate release: Ferriprox (deferiprone) 500 mg immediate release tablet formulation</description>
        </group>
        <group group_id="E5">
          <title>Immediate Release, Fed Conditions</title>
          <description>A single 1000 mg dose of Ferriprox immediate release tablet formulation administered following a high-fat breakfast
Deferiprone immediate release: Ferriprox (deferiprone) 500 mg immediate release tablet formulation</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular Hyperaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Amylase Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Blood Calcium Decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Blood Urine Present</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>C-Reactive Protein Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hepatic Enzyme Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Neutrophil Count Decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urine Odour Abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor retained title to and the right to publish all documentation, records, raw data, specimens or other work product generated in connection with the trial. Such publications shall not be made without the prior written consent of Sponsor. Neither Party will use the other Party's name in connection with any publication or promotion without the other Party's prior written consent. However, Sponsor has the right to publish appropriate information in order to satisfy regulatory requirements.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Caroline Fradette, PhD</name_or_title>
      <organization>ApoPharma Inc.</organization>
      <phone>416-401-7543</phone>
      <email>cfradett@apopharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

